Discuss the regulatory framework governing drug licensing in India under the Drugs and Cosmetics Act, 1940. In this context, examine the significance of the 2026 amendment reclassifying high-alcohol drug formulations from Schedule K to Schedule H1.

Q. Discuss the regulatory framework governing drug licensing in India under the Drugs and Cosmetics Act, 1940. In this context, examine the significance of the 2026 amendment reclassifying high-alcohol drug formulations from Schedule K to Schedule H1. (15 marks, 250-350 words)

The Drugs and Cosmetics Act, 1940 regulates the import, manufacture, distribution and sale of drugs, with licensing under Chapter IV as its core control device [2]. Its Schedules act as calibrated dials of regulation — a flexibility the 2026 Schedule K to H1 shift illustrates well.

Architecture of drug licensing - Statutory base: the Act of 1940, operationalised through the Drugs Rules, 1945, makes manufacture, sale and stocking of drugs licensable activities [2]. - Two-tier regulator: CDSCO/DCGI under the Union Health Ministry handles imports, new drugs and standards, while State Drug Control Authorities grant manufacturing and retail licences — drugs being a Concurrent List subject [4]. - Technical advice: the Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committee advise on Schedule and rule changes [2]. - Schedules calibrate stringency: Schedule H/H1 (prescription-only), Schedule X (strictest, narcotic-type), and Schedule K, which exempts specified categories from licensing [4]. Schedule H1, created by GSR 588(E) of 30 August 2013 for antibiotics, anti-TB and habit-forming drugs, additionally mandates a separate register of patient and prescriber details [3].

Significance of the 2026 amendment - Closes a diversion loophole: the Drugs (Tenth Amendment) Rules, 2026 withdraw the Schedule K exemption for oral formulations containing more than 12% v/v ethyl alcohol in packs above 30 ml, moving them to Schedule H1 [1]. - Public health gain: tinctures and tonics sold over the counter were being misused as intoxicants; sale now requires a registered medical practitioner's prescription [1]. - Cooperative federalism: the Centre acted on references from State governments, though enforcement capacity of State drug inspectorates remains the weak link [1]. - Regulatory agility: achieved through delegated legislation, avoiding fresh parliamentary enactment, with a six-month transition for industry compliance [1].

The amendment shows that India's drug law derives its strength less from new statutes than from responsive use of its Schedules. Sustaining this gain requires strengthened State inspectorates, digital sale registers and pharmacist training, so that access for genuine patients is preserved even as misuse is curbed — advancing the right to health under Article 21 and SDG-3.

(~325 words)

Sources: 1. PIB, "Government amends Drugs Rules, 1945 to Strengthen Regulation of High Alcohol-Containing Drug Formulations" (July 2026) — Drugs (Tenth Amendment) Rules, 2026; 12% v/v and 30 ml thresholds; Schedule K exemption withdrawn; State references; six-month commencement 2. The Drugs and Cosmetics Act, 1940 — India Code — scope of the Act, Chapter IV licensing, DTAB and advisory machinery 3. CDSCO, Public Notice on Inclusion of Schedule H1, GSR 588(E) dated 30.08.2013 — origin and coverage of Schedule H1; separate register and record-keeping duty 4. CDSCO, Drugs and Cosmetics Act, 1940 and Rules, 1945 (compiled text) — Schedule K exemptions, Schedules H/X, Centre–State division of licensing functions